AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Medline shares surge 30.55% intraday after $6.26B IPO values company at $50B.
ByAinvest
Wednesday, Dec 17, 2025 2:06 pm ET1min read
Medline surged 30.55% intraday after completing the year's largest IPO, raising $6.26 billion by selling 216 million shares at $29 each, valuing the medical supply giant at $39 billion. The public offering, upsized due to strong institutional demand, enabled debt reduction and provided liquidity to pre-IPO owners. The stock’s sharp rise followed its Nasdaq debut on December 17, 2025, with shares opening 6.9% above the IPO price. The listing, led by private equity-backed Blackstone, Carlyle, and Hellman & Friedman, marked a pivotal moment for the healthcare supply-chain leader, which operates 69 facilities and delivers to 95% of U.S. customers. Analysts highlighted the IPO’s role in signaling a potential revival of 2026’s IPO market, with Medline’s operational scale, consistent profitability, and deleveraging strategy attracting investor confidence. The debut also underscored the sector’s resilience amid broader market volatility and tariff risks.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet